Cargando…

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene coding for α-galactosidase A (α-GalA). The deleterious mutations lead to accumulation of α-GalA substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine. Progressive glycolipid storage r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welford, R W D, Mühlemann, A, Garzotti, M, Rickert, V, Groenen, P M A, Morand, O, Üçeyler, N, Probst, M R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	General Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140777/ https://www.ncbi.nlm.nih.gov/pubmed/29982630 http://dx.doi.org/10.1093/hmg/ddy248

Ejemplares similares

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease
por: Ishii, Satoshi, et al.
Publicado: (2020)

The Glucosylceramide Synthase Inhibitor PDMP Causes Lysosomal Lipid Accumulation and mTOR Inactivation
por: Hartwig, Pia, et al.
Publicado: (2021)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
por: Guérard, N., et al.
Publicado: (2017)

Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion
por: Kamani, Mustafa A, et al.
Publicado: (2016)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Glucosylceramide synthase maintains influenza virus entry and infection
por: Drews, Kelly, et al.
Publicado: (2020)

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
por: Kim, Jeong-Yup, et al.
Publicado: (2010)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy
por: Liguori, Rocco, et al.
Publicado: (2017)

Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase
por: Nicholson, K M, et al.
Publicado: (1999)

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
por: Najafian, Behzad, et al.
Publicado: (2016)

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
por: Shin, Seok-Ho, et al.
Publicado: (2018)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Role of Globotriaosylceramide in Physiology and Pathology
por: Celi, Ana Beatriz, et al.
Publicado: (2022)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

ARF6 Regulates Neuron Differentiation through Glucosylceramide Synthase
por: Li, Lu, et al.
Publicado: (2013)

New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression
por: Gupta, Vineet, et al.
Publicado: (2013)

Glucosylceramide Synthase Is Involved in Development of Invariant Natural Killer T Cells
por: Popovic, Zoran V., et al.
Publicado: (2017)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
por: Birklé, Stéphane, et al.
Publicado: (2013)

Control of Glucosylceramide Production and Morphogenesis by the Bar1 Ceramide Synthase in Fusarium graminearum
por: Rittenour, William R., et al.
Publicado: (2011)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia
por: Wang, Liping, et al.
Publicado: (2022)

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

Doxorubicin Influences the Expression of Glucosylceramide Synthase in Invasive Ductal Breast Cancer
por: Zhang, Xiaofang, et al.
Publicado: (2012)

Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase
por: Henriques, Alexandre, et al.
Publicado: (2015)

Plasma Lysosphingomyelin Demonstrates Great Potential as a Diagnostic Biomarker for Niemann-Pick Disease Type C in a Retrospective Study
por: Welford, Richard W. D., et al.
Publicado: (2014)

MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease
por: Maier, Nadine, et al.
Publicado: (2021)

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
por: Stefanovic, Milica, et al.
Publicado: (2016)

Glucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking
por: Andersson, Linda, et al.
Publicado: (2021)

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
por: Baccam, Gabriel C., et al.
Publicado: (2022)

Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous system
por: Avraham, Roy, et al.
Publicado: (2023)

Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease
por: An, Jong Hun, et al.
Publicado: (2022)

Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export
por: Martin, Shaun, et al.
Publicado: (2020)

Risk of Death in Heart Disease is Associated With Elevated Urinary Globotriaosylceramide
por: Schiffmann, Raphael, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cevn9v4vtha063vuuqoup0vh0q